Visão geral da empresa
A clinical-stage biotechnology enterprise, Jasper Therapeutics, Inc. is dedicated to the development of novel therapeutics specifically targeting mast and hematopoietic stem cell driven diseases, with its primary product candidate being briquilimab, a monoclonal antibody engineered to inhibit stem cell factor signaling pathways. The company operates within the broader Healthcare sector, specifically classified under the Biotechnology industry, which implies a focus on high-risk, high-reward research and development activities aimed at discovering and commercializing innovative medical treatments. As of the latest available data, the firm maintains a market capitalization of $23.06M and employs a workforce of 22 individuals, reflecting a lean organizational structure typical of early-phase biotech entities. These financial metrics indicate that Jasper Therapeutics functions as a micro-cap entity with limited operational scale, suggesting that its current market valuation is heavily reliant on the potential future success of its pipeline rather than established commercial revenue streams or a large existing customer base.
Saúde financeira
The financial performance of Jasper Therapeutics, Inc. reveals a significant cash burn profile, characterized by a net income loss of $-75,801,000 and an EBITDA of $-80,527,000, while the reported revenue for the trailing twelve months remains N/A due to the company's current clinical-stage status. The substantial gap between the nominal revenue and the deep net losses highlights a cost structure dominated by research and development expenditures and operational overheads necessary to advance drug candidates through clinical trials rather than sales activities. Additionally, the company reported a free cash flow of $-47,189,376, indicating a continuous outflow of capital that necessitates ongoing access to external financing or the utilization of existing cash reserves to sustain operations. When analyzing profitability metrics, the gross margin, operating margin, and profit margin are all recorded at 0.0%, which is consistent with a company that has not yet generated commercial sales but has incurred significant expenses in the pursuit of product development. Despite the losses, the balance sheet shows a cash position of $28.69M against a total debt load of only $1.24M, resulting in a debt-to-equity ratio of 29.75, which suggests a highly leveraged classification in traditional terms but indicates minimal actual debt burden for a pre-revenue biotech firm. Furthermore, the current ratio stands at 2.62, signaling robust short-term liquidity and the ability to cover current liabilities with current assets, providing a safety buffer for the company's cash burn rate. Finally, the return on equity is -230.3% and the return on assets is -88.2%, metrics that reflect the dilutive impact of equity issuance or accumulated losses on the base of capital employed and confirm that management is currently sacrificing immediate returns to fund long-term scientific milestones.
Avaliação de valorização
The valuation multiples for Jasper Therapeutics, Inc. present a challenging picture for traditional metrics, with a trailing P/E ratio of N/A due to negative earnings and a forward P/E of -0.49, which implies that the market is pricing in the expectation that the company will eventually return to profitability or that the current negative earnings are not yet a reliable indicator of future cash generation. The price-to-book ratio is calculated at 5.56, suggesting that the market values the company at a significant premium over its book value, a phenomenon often observed in biotech firms where the intangible value of the intellectual property and pipeline outweighs the tangible assets recorded on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio, which is listed as N/A given the lack of revenue, and an EV/EBITDA of 0.06, further illustrate the difficulty in applying standard valuation models to a company that has not yet crossed the commercialization threshold. In terms of trading ranges, the stock has fluctuated between a 52-week high of $7.19 and a 52-week low of $0.65, indicating a high degree of price instability and a wide dispersion in investor sentiment regarding the asset's potential. Although the current price is not explicitly stated in the provided facts, the beta value of 3.20 indicates that the stock is highly volatile and is expected to move with more than three times the magnitude of the broader market, reflecting the heightened risk associated with speculative biotechnology investments.
Growth & Income
Regarding growth dynamics, the revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, which is expected for a clinical-stage company that has not yet established a commercial sales history or consistent earnings trajectory. Consequently, it is impossible to determine whether earnings are growing faster or slower than revenue in a traditional sense, as the company is currently in a phase where capital allocation is directed entirely toward advancing its lead candidate, briquilimab, rather than expanding sales volumes. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning that all available earnings or cash reserves are theoretically available for reinvestment into research, development, and operational scaling rather than being distributed to shareholders. This profile characterizes Jasper Therapeutics, Inc. as a pure growth vehicle with no current income generation, where the primary objective is to de-risk the clinical pipeline and achieve regulatory approval for its therapeutic products.